Company Overview of CoLucid Pharmaceuticals, Inc.
CoLucid Pharmaceuticals, Inc., a biopharmaceutical company, develops therapies for the treatment of central nervous system disorders. Its pipeline includes Lasmiditan, a neurally acting anti-migraine agent that is designed to deliver efficacy in migraine without the vasoconstrictor activity associated with previous generations of migraine therapies; COL-204 for wake promotion; and a Conjugated Stigmines platform that has generated a series of preclinical candidates for the chronic pain, Alzheimer's disease, and psychiatric disorders. CoLucid Pharmaceuticals, Inc. was founded in 2005 and is based in Durham, North Carolina.
2530 Meridian Parkway
Durham, NC 27713
Founded in 2005
Key Executives for CoLucid Pharmaceuticals, Inc.
Chief Executive Officer and Director
Legal Counsel and Director
Vice President of Business Development
Vice President of Research & Development
Compensation as of Fiscal Year 2014.
CoLucid Pharmaceuticals, Inc. Key Developments
CoLucid Pharmaceuticals, Inc. Presents at 13th Annual BIO Investor Forum, Oct-08-2014 09:30 AM
Aug 6 14
CoLucid Pharmaceuticals, Inc. Presents at 13th Annual BIO Investor Forum, Oct-08-2014 09:30 AM. Venue: The Palace Hotel, San Francisco, CA 94105, United States.
CoLucid Pharmaceuticals, Inc., Announces Agreement from the FDA on a Special Protocol Assessment (SPA) for the Phase 3 Trial of Lasmiditan
May 6 14
CoLucid Pharmaceuticals, Inc. has reached agreement with the U.S. Food and Drug Administration (FDA) for the planned SAMURAI study. The objective of this trial is to evaluate the safety and efficacy of two doses of Lasmiditan in comparison to placebo for the treatment of acute migraine. Patients with risk factors for cardiovascular disease will be included in the study. The SPA agreement includes two novel endpoints for the approval of acute migraine therapies—a primary endpoint of the proportion of patients who are free of headache pain at 2 hours and a key secondary endpoint of the proportion of patients who no longer suffer from their most bothersome associated symptom of migraine (nausea, photophobia, phonophobia) at 2 hours.
CoLucid Pharmaceuticals and ILDONG Pharmaceutical Enter into a Distribution and Supply Agreement for Lasmiditan
Oct 23 13
CoLucid Pharmaceuticals, Inc. and ILDong Pharmaceutical Co. Ltd. have entered into a distribution and supply agreement for Lasmiditan in South Korea and Southeast Asia. Under the terms of the agreement, CoLucid will receive upfront and milestone payments in addition to consideration for product supply in exchange for exclusive rights to ILDONG for development and commercialization of Lasmiditan in the territory. ILDONG will be responsible for the costs and activities related to development and regulatory approvals in the territory and will also participate in key registration trials as part of the global development plan.
Similar Private Companies By Industry
Recent Private Companies Transactions
January 12, 2015
Most Searched Private Companies
Sponsored Financial Commentaries